Proteasome inhibitors as therapeutics

Essays in Biochemistry

Volumn 41, Issue , 2005, Pages 205-218

  Mitsiades, Constantine S ^a,b   Mitsiades, Nicholas ^a,b   Hideshima, Teru ^a,b   Richardson, Paul G ^a,b   Anderson, Kenneth C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27144527863     PISSN: 00711365     EISSN: None     Source Type: Journal    
DOI: 10.1042/bse0410205     Document Type: Review

References (52)

1. Ciechanover, A. (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79, 13-21
2. Adams, J. (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417-421
3. DeMartino, G.N. & Slaughter, C.A. (1999) The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274, 22123-22126
4. Goldberg, A.L., Akopian, T.N., Kisselev, A.F., Lee, D.H. & Rohrwild, M. (1997) New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biol. Chem. 378, 131-140
5. Palombella, V.J., Rando, O.J., Goldberg, A.L. & Maniatis, T. (1994) The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773-785
6. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N., Treon, S.P. & Anderson, K.C. (2002) Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 99, 4079-4086
7. Kisselev, A.F. & Goldberg, A.L. (2001) Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8, 739-758
8. Adams, J., Behnke, M., Chen, S., Cruickshank, A.A., Dick, L.R., Grenier, L., Klunder, J.M., Ma, Y.T., Plamondon, L. & Stein, R.L. (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333-338
9. Almond, J.B. & Cohen, G.M. (2002) The proteasome: a novel target for cancer chemotherapy. Leukemia 16, 433-443
10. Orlowski, R.Z., Eswara, J.R., Lafond-Walker, A., Grever, M.R., Orlowski, M. & Dang, C.V. (1998) Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 58, 4342-4348
11. Masdehors, P., Merle-Beral, H., Magdelenat, H. & Delic, J. (2000) Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk. Lymphoma 38, 499-504
12. Cusack, Jr, J.C., Liu, R., Houston, M., Abendroth, K., Elliott, P.J., Adams, J. & Baldwin, Jr, A.S. (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res. 61, 3535-3540
13. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. & Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622
14. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-3076
15. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Treon, S.P. et al. (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. U.S.A. 99, 14374-14379
16. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N.C., Treon, S.P. & Anderson, K.C. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99, 4525-4530
17. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M. et al. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377-2380
18. Pham, L.V., Tamayo, A.T., Yoshimura, L.C., Lo, P. & Ford, R.J. (2003) Inhibition of constitutive NF-kB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J. Immunol. 171, 88-95
19. Teicher, B.A., Ara, G., Herbst, R., Palombella, V.J. & Adams, J. (1999) The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5, 2638-2645
20. Frankel, A., Man, S., Elliott, P., Adams, J. & Kerbel, R.S. (2000) Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 6, 3719-3728
21. Shah, S.A., Potter, M.W., McDade, T.P., Ricciardi, R., Perugini, R.A., Elliott, P.J., Adams, J. & Callery, M.P. (2001) 26 S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem. 82, 110-122
22. MacLaren, A.P., Chapman, R.S., Wyllie, A.H. & Watson, C.J. (2001) p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ. 8, 210-218
23. Guzman, M.L., Swiderski, C.F., Howard, D.S., Grimes, B.A., Rossi, R.M., Szilvassy, S.J. & Jordan, C.T. (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. U.S.A. 99, 16220-16225
24. Lee, A.H., Iwakoshi, N.N., Anderson, K.C. & Glimcher, L.H. (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. U.S.A. 100, 9946-9951
25. Mitsiades, C.S., Mitsiades, N., Poulaki, V., Schlossman, R., Akiyama, M., Chauhan, D., Hideshima, T., Treon, S.P., Munshi, N.C., Richardson, P.G. & Anderson, K.C. (2002) Activation of NF-kB and upregulation of intracellular anti-apoptotic proteins via the IGF-I/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogens 21, 5673-5683
26. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Anderson, K.C. & Treon, S.P. (2002) Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 99, 2162-2171
27. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Anderson, K.C. & Treon, S.P. (2001) Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias. Expert Opin. Invest. Drugs 10, 1521-1530
28. Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T.A. & Anderson, K.C. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kB. Blood 87, 1104-1112
29. Barut, B.A., Zon, L.I., Cochran, M.K., Paul, S.R., Chauhan, D., Mohrbacher, A., Fingeroth, J. & Anderson, K.C. (1992) Role of interleukin 6 in the growth of myeloma-derived cell lines. Leuk. Res. 16, 951-959
30. Drexler, H.C. (1997) Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. U.S.A. 94, 855-060
31. Drexler, H.C., Risau, W. & Konerding, M.A. (2000) Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J. 14, 65-77
32. Masdehors, P., Omura, S., Merle-Beral, H., Mentz, F., Cosset, J.M., Dumont, J., Magdelenat, H. & Delic, J. (1999) Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematol. 105, 752-757
33. Adams, J. (2004) The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4, 349-360
34. Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D.L., Elliott, P.J., Pien, C.S. et al. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420-4427
35. Cortes, J., Thomas, D., Koller, C., Giles, F., Estey, E., Faderl, S., Garcia-Manero, G., McConkey, D., Patel, G., Guerciolini, R. et al. (2004) Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 10, 3371-3376
36. Aghajanian, C., Soignet, S., Dizon, D.S., Pien, C.S., Adams, J., Elliott, P.J., Sabbatini, P., Miller, V., Hensley, M.L., Pezzulli, S. et al. (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8, 2505-2511
37. Papandreou, C.N., Daliani, D.D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C.S., Millikan, R.E., Tu, S.M., Pagliaro, L. et al. (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 22, 2108-2121
38. Adams, J. (2002) Development of the proteasome inhibitor PS-341. Oncologist 7, 9-16
39. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R. et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617
40. Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P.G., Niesvizky, R., Alexanian, R., Limentani, S.A., Alsina, M. et al. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. 127, 165-172
41. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Dalton, W.S., Harousseau, J.L., San Miguel, J.F. & Anderson, K.C. (2005) Bortezomib vs. dexamethasone in relapsed multiple myeloma: a phase 3 randomized study. N. Engl. J. Med. in the press
42. Mitsiades, C.S., Mitsiades, N., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., Chauhan, D., Treon, S.P., Richardson, P.G., Munshi et al. (2003) The proteasome inhibitor bortezomib (PS-341) is active against Waldenstrom's macroglobulinemia (WM). Blood 102 (suppl), Abstract no. 631
43. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J.E., Hagemeister, F., Fayad, L., Dang, N.H., Samaniego, F., Wang, M. et al. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 667-675
44. O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E. et al. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 23, 676-684
45. Kondagunta, G.V., Drucker, B., Schwartz, L., Bacik, J., Marion, S., Russo, P., Mazumdar, M. & Motzer, R.J. (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol. 22, 3720-3725
46. Davis, N.B., Taber, D.A., Ansari, R.H., Ryan, C.W., George, C., Vokes, E.E., Vogelzang, N.J. & Stadler, W.M. (2004) Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J. Clin. Oncol. 22, 115-119
47. Dragovich, T., Lenz, H.J., Rocha Lima, C.M.S., Kozuch, P., Hochster, H., O'Neil, B., Atiq, O., Pipas, J.M., Kashala, O. & Schenkein, D.P. (2004) Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): interim analysis results from a phase 2b study. J. Clin. Oncol. 22 (Suppl.), 267s (Abstract)
48. Fanucchi, M.P., Belt, R.J., Fossella, F.V., Natale, B., Robert, F., Fidias, P., Kelly, K., Kashala, O., Schenkein, D.P. & Schiller, J.H. (2004) Phase (ph) 2 study of bortezomib ± docetaxel inpreviously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). Preliminary results. J. Clin. Oncol. 22 (Suppl.), 643s (Abstract)
49. Dreicer, R., Roth, B., Petrylak, D., Agus, D., Meyers, M., Esseltine, D., Rodriquez, D., Oppedisano, P., Wang, K. & Boral, A.(2004) Phase I/II trial of VELCADE® plus docetaxel in patients with advanced androgen-independent prostate cancer. J. Clin. Oncol. 22 (Suppl.), 420s (Abstract)
50. Shah, M.H., Young, D., Kindler, H.L., Webb, I., Kleiber, B., Wright, J. & Grever, M. (2004) Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 10, 6111-6118
51. Stevenson, J., Nho, C.W., Johnson, S.W. et al. (2004) Phase II/pharmacodynamic trial of PS-341 (bortezomib, VELCADE®) in advanced non-small cell lung cancer. J. Clin. Oncol. 22 (Suppl.), 652s (Abstract)
52. Hegewisch-Becker, S., Sterneck, M., Schubert, U., Rogiers, X., Guerciolini, R., Pierce, J.E. & Hossfeld, D.K. (2004) Phase I/II trial of bortezomib (VELCADE®) in patients with unresectable hepatocellular carcinoma. J. Clin. Oncol. 22 (Suppl.), 335s (Abstract)